Neovasc Inc

Neovasc — OneMedForum 2011

17 slides from Neovasc's conference presentation, January 2011

  1. Slide 1: Neovasc Inc.

    Neovasc Inc. Alexei Marko, CEO OneMedForum 2011

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo

  3. Slide 3: Neovasc at-a-Glance

    Neovasc at-a-Glance • Medical device company focused on innovative products to treat heart disease and related conditions • Two key product lines with large growth potential : 1. Neovasc Reducer™ for treatment of refractory angina 2. Implantable biological tissue and services for transcatheter heart

  4. Slide 4: Reducer Product Summary: Treats Refractory Angina

    Reducer Product Summary Treats Refractory Angina • Inadequate blood flow to heart muscle that cannot be managed through conventional drug, catheter or surgical therapy • Causes constant and severe heart pain and significant disability that negatively impacts quality of life • Large untreatable patie

  5. Slide 5: Reducer Market Opportunity

    Reducer Market Opportunity • Estimated selling price $3,000 - $5,000 • ~ 2 million existing “no option” refractory angina patients in US & Europe ($6B potential market) • ~400,000 new “no option” patients diagnosed annually ($1.2B potential market) • ~1 million patients/year in US & Europe undergo r

  6. Slide 6: Reducer – How It Works

    Reducer – How It Works Reducer restricts outflow of blood from coronary veins, forcing oxygenated blood deeper into the heart muscle where it reaches oxygen-starved ischemic areas Reducer Increased venous back pressure forces blood into ischemic areas

  7. Slide 7: Reducer Procedure

    Reducer Procedure • Treating refractory angina by narrowing coronary sinus based on a surgical procedure performed in 1960’s (Beck Procedure) • Beck Procedure reported excellent results but is no longer performed due to invasiveness of the surgery • Neovasc Reducer achieves same narrowing, but using

  8. Slide 8: Reducer Clinical Results

    Reducer Clinical Results Compelling clinical data from first human trial (15 patients, 3 centers) • Six-month data published in May 2007 JACC demonstrated safety and significant improvement of angina symptoms • Three-year follow-up data confirms excellent long-term safety and durability of treatment

  9. Slide 9: COSIRA Trial for CE Mark Application

    Reducer COSIRA Trial for CE Mark Application COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) Double-blind, randomized, sham-controlled, multicenter, prospective trial • 124 patients • Randomized 1:1 to blinded treatment and sham control arms • Primary endpoint: Efficacy @ 6-months

  10. Slide 10: Advisors Include Key Opinion Leaders

    Advisors Include Key Opinion Leaders Leaders in interventional cardiology and refractory angina are working on the Reducer program • Dr. Shmuel Banai (Tel Aviv Souraski Medical Center) • Dr. Elazer Edelman (Harvard – MIT, Cambridge) • Dr. Tim Henry (Minneapolis Heart Institute) • Dr. Marc Jolicoeur

  11. Slide 11: Reducer Commercialization Timeline

    Reducer Commercialization Timeline • Commercial product completed • Europe: COSIRA to provide data for CE mark and European launch (early 2012) • US: FDA trial and approval process (PMA) will be initiated following European CE mark approval (commence mid 2012)

  12. Slide 12: Biological Tissue Products

    Biological Tissue Products • Proprietary process creates implantable, biocompatible tissue that retains strength and physical characteristics of natural tissue • Developed specifically for surgical heart valve applications • Adapted for general surgical use as a patch or reinforcement material • FDA

  13. Slide 13: Rapid Growth in Heart Valve Applications

    Rapid Growth in Heart Valve Applications Neovasc is the leading independent supplier of biological leaflet material to companies developing transcatheter heart valves. • Clear clinical need and market support for transcatheter aortic valve therapies (TAVI) • Acquisitions of Ventor, Corevalve, Evalve

  14. Slide 14: Other Applications & Services

    Other Applications & Services • Artificial heart components • Specialty vascular devices • Vascular surgical patches (LeMaitre Vascular’s Xenosure™) • Surgical patches for non-vascular use State-of-the-art facility and highly experienced team with expertise in tissue valve and vascular device develo

  15. Slide 15: 2011: Looking Forward

    2011: Looking Forward Continued growth in revenues from tissue business (target >$5M) • Expect steady growth over next 12 months with upside potential in late 2011 and 2012 as customers’ products enter market Complete COSIRA trial for Reducer and file CE-mark application to allow sale in Europe • Pr

  16. Slide 16: Capitalization & Trading

    Capitalization & Trading • 40.4m (issued and outstanding) Shares outstanding • 44.8m (fully diluted) Public listing • TSX-V: NVC • Frost Group (Dr. Phillip Frost) Key investors • Company management Financing • 12+ months cash on hand based on forecast burn

  17. Slide 17: Thank you

    Thank you Qs

Neovasc — OneMedForum 2011 on 6ix